TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02680782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: 100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD. Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X4P-001
Description: 100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD. Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.
Study: NCT02495948

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses
Study: NCT01902173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprosertib
Description: Given PO
Study: NCT02252172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab IV
Description: Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg orally or intravenously once in a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg orally or intravenously once in a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab SC
Description: Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study end. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator.
Study: NCT02495948

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Samfilcon A contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Samfilcon A contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrogen peroxide solution
Description: Used as a cleaning, disinfection, and storage solution for silicone hydrogel and soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrogen peroxide solution
Description: Used as a cleaning, disinfection, and storage solution for silicone hydrogel and soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Saline solution
Description: Used for rinsing contact lenses, as needed

Intervention type: DEVICE
Group type: OTHER
Intervention: Saline solution
Description: Used for rinsing contact lenses, as needed
Study: NCT02022449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management
Description: Cognitive behavioral stress management Cognitive and emotionally focused coping enhancement strategies Progressive muscle relaxation Social support Strategies for parenting a child with cancer
Study: NCT01822002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Canalith repositioning maneuver

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Canalith repositioning maneuver
Study: NCT01543347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temocillin
Description: Antibiotic treatment
Study: NCT01481896

Intervention type: DEVICE
Intervention: Metal-on-metal primary total hip arthroplasty (DePuy )
Description: Replacement of a patient's native hip with an artificial implant featuring a metal-on-metal articulation
Study: NCT00165958

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excisional surgery of epidermal cyst
Description: Traditional extirpation of cyst en toto

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch incision of epidermal cyst
Description: removal of cyst first with incisional effort with a punch biopsy tool
Study: NCT03152240

Intervention type: OTHER
Intervention: Non intervention
Description: Non intervention

Intervention type: OTHER
Intervention: Non intervention
Description: Non intervention
Study: NCT03830216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected insulin pen and smartphone app
Description: The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is paired with a smartphone app with dose calculator.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive connected insulin pen without smartphone app
Description: The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is inactive and not paired with a smartphone app or dose calculator.
Study: NCT02251912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: 10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 insufflations (same solution as active treatment minus oxytocin) given 3 initially and then 2 times daily for 12 weeks
Study: NCT02168595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Description: GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Description: GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Description: GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03790592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trifocal IOL
Description: intraocular lens
Study: NCT03325179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thread-embedding Therapy
Study: NCT02472522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Dexmedetomidine
Description: Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine and 1 micrograms/kg dexmedetomidine (combination drug) diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
Study: NCT02173093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GD2Bi-aATC
Description: Given IV
Study: NCT01998542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloVax
Description: Personalized anti-cancer vaccine with AlloStim(TM) and CRCL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRCL
Description: autologous tumor-derived chaperone protein mixture

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: AlloStim (ID) injection AlloStim (IV) infusion
Study: NCT04055103

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monthly feedback, education and linking hospitals
Description: - Give monthly feedback from LROI-data (revision rate \& patient reported outcome measures) as well as other outcomes from the participating hospital (length-of-stay, readmission and complications), combined with education on how to use this information for improvement. This will be send monthly by email to the intervention group. Further, hospitals with worse performance for a certain outcome will be linked to hospitals with good performance for this outcome.
Study: NCT05257512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-3505
Description: The third-generation ALK TKI
Study: NCT03135912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Drug SESC 01
Description: Topical experimental treatment comprising a combination of approved topical therapies and a new dosage method.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage method of SESC 01, without active ingredients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride
Description: Topical terbinafine hydrochloride cream.
Study: NCT02266433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study~Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is a synthetic corticosteroid and possesses glucocorticoid activity, and will be used within its labeled indication for this study: intra-articular or soft tissue injection for: synovitis of osteoarthritis, epicondylitis, acute nonspecific tenosynovitis. It is the active comparator in this study.~In its approved indication there use limitations for immunocompromised individuals, pregnant females, persons with allergy to steroids, individuals with systemic fungal infections, and individuals with cerebral malaria. It is contra-indicated in systemic fungal infections, and hypersensitivity to any component of this product, including sulfites.
Study: NCT01745757

Intervention type: DRUG
Intervention: Bevacizumab
Description: Treatments received by patients in this study are prescribed in the context of standard care

Intervention type: DRUG
Intervention: paclitaxel
Description: Treatments received by patients in this study are prescribed in the context of standard care
Study: NCT04620330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766)
Description: Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and Defactinib
Description: Combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and Defactinib
Description: Combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and Defactinib
Description: Combination therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib (VS-6766) and Defactinib
Description: Combination therapy
Study: NCT04391725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periapical surgery with guided tissue regeneration
Description: periapical surgery will be done followed by placement of mixture of iPRF and type 1 collagen granules

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periapical surgery without anyguided tissue regeneration
Description: periapical surgery will be done followed by flap closure
Study: NCT04364919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise program
Description: The program incorporated modified yoga movements suitable for pregnant women. The DVD provides an illustration with the written caption, Please take enough water before exercise, and wear loose and comfortable clothes in a suitable environment. If you feel tired, stop exercising immediately. The DVD's narrator then says, Now you are ready to prepare a comfortable, solid chair with a chair back. With a soft musical background, the exercise actions were arranged in following order: warm-up → neck → shoulder → arm → chest → waist →leg → regulating the breathing. The first 14.5 minutes of the yoga exercises were performed in a sitting position, followed by 3.5 minutes in standing position, and then returning to 2 minutes in sitting position. The exercises were developed as a progressive program in order to achieve the goals of strength-conditioning, moderate-intensity exercise (ACOG, 2015).
Study: NCT03324360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: MRI with Hyperpolarized 13C-Pyruvate Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: MRI with Hyperpolarized 13C-Pyruvate Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: MRI with Hyperpolarized 13C-Pyruvate Injection
Study: NCT04741269

Intervention type: DIAGNOSTIC_TEST
Intervention: Find a link between lack of knee flexion and meniscal posterior luxation fixed
Description: Measure the full flexion angle of the knee using a goniometer. Measure the heel-buttom distance. All measurements are carried out in bilateral and comparative ways.~Search for the meniscal position on MRI and intraoperatively: no shift, anterior, medial, posterior shift.
Study: NCT03190057

Intervention type: DEVICE
Intervention: BIOFREEDOM™ FAMILY stent
Description: Percutaneous coronary intervention with BIOFREEDOM™ FAMILY stent
Study: NCT02602223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placing Amnion chorion membrane over grafted site
Description: Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol ACM (BioXclude, Snoasis Medical, Colorado, U.S.A were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placing d-PTFE membrane over grafted site
Description: Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol d-PTFE membranes (Cytoplast, Osteogenics Medical, Texas, U.S.A) were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
Study: NCT01121380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-1021
Description: BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 \& 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-1021
Description: BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 \& 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-1021
Description: BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 \& 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-1021
Description: BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 \& 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results.
Study: NCT02173093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory evaluations of immune responses
Description: Correlative studies
Study: NCT00830895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 10mg/day
Study: NCT01121380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-1021
Description: BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 \& 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-1021
Description: BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 \& 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-1021
Description: BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 \& 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1021
Description: 1021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1021
Description: 1021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1021
Description: 1021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1021
Description: 1021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1021
Description: 1021
Study: NCT03482934

Intervention type: DEVICE
Intervention: sphygmomanometer
Description: device used for measurement of brachial blood pressure

Intervention type: DEVICE
Intervention: mobilogragh
Description: device used for measurement of central blood pressure

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: Electrocardiogram

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography
Study: NCT01121380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1021
Description: 1021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1021
Description: 1021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1021
Description: 1021
Study: NCT00766805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVL + Propranolol + Isosorbide 5 mononitrate
Description: Treatment was started with propranolol at a dose of 40 mg twice a day. The heart rate and blood pressure were checked after 12 to 24 hours. The dose of propranolol was increased at increments of 20 to 40 mg per day until the patient achieved a heart rate of 55 bpm, or a maximum dose of 320 mg/day was achieved.ISMN was added at a dose of 10 mg twice a day. The dose was escalated at increments of 10-20 mg/day till a maximum dose of 40 mg/day was reached.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EVL alone
Study: NCT00685594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 20.000 IU cholecalciferol per week for 5 years versus placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once a week, identical to cholecalciferol capsule
Study: NCT01859247

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Study: NCT01119235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04531083
Description: Dosed as a tablet in 100mg strengths. Dosage in the first cohort will be 300mg twice daily for 3 days followed by 200mg twice daily for 11 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04531083
Description: Dosed as a tablet in 100mg strengths. Dosage in this optional second cohort will be optimised based on the data arising from Cohort 1